中国医药收购则正医药，加速构建研产销一体化新生态

Core Insights - China Medical (600056.SH) announced the acquisition of 70% stake in Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for RMB 525 million, marking a significant step in enhancing its R&D capabilities and integrating the entire industry chain from R&D to production [1][2] Group 1: Acquisition Details - The acquisition will allow Zezheng Pharmaceutical to become a subsidiary of China Medical, thus included in its consolidated financial statements [1] - Zezheng Pharmaceutical, established in 2017, specializes in modified new drugs and complex formulations, with over 100 R&D projects submitted to the National Medical Products Administration and 55 drug approvals obtained [1] Group 2: Strategic Implications - The acquisition aims to fill the gaps in China Medical's capabilities in generic drugs, modified new drugs, and innovative drugs, facilitating the upgrade of its product pipeline [1] - By combining Zezheng Pharmaceutical's CRO services with China Medical's industrial capacity, the transaction is expected to accelerate the conversion of technological achievements and create a competitive edge in high-barrier areas like complex formulations [1] - The retention of Zezheng Pharmaceutical's core team post-acquisition is intended to ensure operational stability [1] Group 3: Industry Context - Industry experts highlight that in the context of national encouragement for pharmaceutical innovation and the normalization of generic drug consistency evaluations, CRO companies with comprehensive R&D capabilities and differentiated technology platforms hold unique advantages [2] - The integration of resources through this acquisition is anticipated to foster a collaborative ecosystem of "R&D—Manufacturing—Commercialization," enhancing overall competitiveness [2]